益佰制药
(600594)
| 流通市值：29.46亿 | | | 总市值：29.46亿 |
| 流通股本：7.92亿 | | | 总股本：7.92亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 358,837,040.95 | 1,862,920,853.13 | 1,446,704,488.11 | 993,123,553.98 |
| 营业收入 | 358,837,040.95 | 1,862,920,853.13 | 1,446,704,488.11 | 993,123,553.98 |
| 二、营业总成本 | 374,652,779.96 | 2,001,366,895.95 | 1,507,739,253.7 | 1,008,735,825.93 |
| 营业成本 | 150,985,925.19 | 751,460,808.48 | 574,014,485.11 | 390,755,013.32 |
| 税金及附加 | 8,511,918.69 | 31,457,220.29 | 25,682,877.22 | 17,984,441.75 |
| 销售费用 | 137,626,547.14 | 822,931,542.08 | 621,405,641.58 | 416,905,726.45 |
| 管理费用 | 58,623,429.15 | 290,532,433.13 | 208,244,548.04 | 136,581,905.42 |
| 研发费用 | 13,469,997.18 | 84,269,082.59 | 62,424,046.36 | 37,113,259.88 |
| 财务费用 | 5,434,962.61 | 20,715,809.38 | 15,967,655.39 | 9,395,479.11 |
| 其中:利息费用 | 5,691,450.14 | 23,374,518.45 | 17,414,473.41 | 10,135,065.05 |
| 其中:利息收入 | 485,260.48 | 3,767,249.28 | 2,788,148.66 | 1,655,292.98 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -5,196.72 | -214,599.61 | -360,755.35 | -512,541.25 |
| 资产处置收益 | 1,836,628.72 | -27,210,380.43 | -19,356,618.36 | 17,429.53 |
| 资产减值损失(新) | -12,212,528.62 | -159,485,265.14 | -23,878,141.91 | -17,658,871.98 |
| 信用减值损失(新) | 47,826.78 | -2,794,771.52 | -2,798,355.96 | -1,092,679.76 |
| 其他收益 | 4,244,601.78 | 24,168,885.77 | 17,511,400.42 | 14,014,471.76 |
| 四、营业利润 | -21,904,407.07 | -303,982,173.75 | -89,917,236.75 | -20,844,463.65 |
| 加:营业外收入 | 1,363,626.27 | 4,710,784.35 | 3,169,170.59 | 1,060,456.84 |
| 减:营业外支出 | 334,699.8 | 12,476,946.3 | 6,268,541.07 | 4,062,310.46 |
| 五、利润总额 | -20,875,480.6 | -311,748,335.7 | -93,016,607.23 | -23,846,317.27 |
| 减:所得税费用 | 8,087,807.44 | 23,593,549.41 | -2,386,803.26 | -1,488,413.09 |
| 六、净利润 | -28,963,288.04 | -335,341,885.11 | -90,629,803.97 | -22,357,904.18 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -28,963,288.04 | -335,341,885.11 | -90,629,803.97 | -22,357,904.18 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -29,524,902.89 | -329,562,325.95 | -86,562,621.79 | -19,902,057.59 |
| 少数股东损益 | 561,614.85 | -5,779,559.16 | -4,067,182.18 | -2,455,846.59 |
| 扣除非经常损益后的净利润 | -34,801,324.57 | -325,096,335.78 | -84,450,585.59 | -31,062,984.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.04 | -0.42 | -0.11 | -0.03 |
| (二)稀释每股收益 | -0.04 | -0.42 | -0.11 | -0.03 |
| 八、其他综合收益 | - | -164,440.9 | -16,696.42 | 13,486.5 |
| 归属于母公司股东的其他综合收益 | - | -164,440.9 | -16,696.42 | 13,486.5 |
| 九、综合收益总额 | -28,963,288.04 | -335,506,326.01 | -90,646,500.39 | -22,344,417.68 |
| 归属于母公司股东的综合收益总额 | -29,524,902.89 | -329,726,766.85 | -86,579,318.21 | -19,888,571.09 |
| 归属于少数股东的综合收益总额 | 561,614.85 | -5,779,559.16 | -4,067,182.18 | -2,455,846.59 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-30 | 2025-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |